Vcanbio Cell & Gene Engineering Corp Ltd Asset Resilience Ratio
Vcanbio Cell & Gene Engineering Corp Ltd asset resilience ratio. Vcanbio Cell & Gene Engineering Corp Ltd (600645) has an Asset Resilience Ratio of 2.86% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600645 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vcanbio Cell & Gene Engineering Corp Ltd (1996–2025)
Asset resilience ratio of Vcanbio Cell & Gene Engineering Corp Ltd from 1996 to 2025. This chart shows how Vcanbio Cell & Gene Engineering Corp Ltd's Asset Resilience Ratio has changed over time. Read Vcanbio Cell & Gene Engineering Corp Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vcanbio Cell & Gene Engineering Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600645 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥150.61 Million | 2.86% |
| Total Liquid Assets | CN¥150.61 Million | 2.86% |
Asset Resilience Insights
- Limited Liquidity: Vcanbio Cell & Gene Engineering Corp Ltd maintains only 2.86% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vcanbio Cell & Gene Engineering Corp Ltd Industry Peers by Asset Resilience Ratio
Compare Vcanbio Cell & Gene Engineering Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Vcanbio Cell & Gene Engineering Corp Ltd Asset Resilience Ratio by Year (1996–2025)
Vcanbio Cell & Gene Engineering Corp Ltd asset resilience ratio by year from 1996 to 2025. The table below shows the annual Asset Resilience Ratio data for Vcanbio Cell & Gene Engineering Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.45% | CN¥712.05 Million ≈ $104.20 Million |
CN¥5.29 Billion ≈ $774.42 Million |
+5.24pp |
| 2019-12-31 | 8.22% | CN¥401.67 Million ≈ $58.78 Million |
CN¥4.89 Billion ≈ $715.35 Million |
+7.75pp |
| 2017-12-31 | 0.47% | CN¥14.00 Million ≈ $2.05 Million |
CN¥3.00 Billion ≈ $438.99 Million |
-3.83pp |
| 2016-12-31 | 4.30% | CN¥129.10 Million ≈ $18.89 Million |
CN¥3.00 Billion ≈ $439.53 Million |
+4.30pp |
| 2015-12-31 | 0.00% | CN¥4.25K ≈ $621.91 |
CN¥2.82 Billion ≈ $412.09 Million |
-15.20pp |
| 2014-12-31 | 15.20% | CN¥367.39 Million ≈ $53.76 Million |
CN¥2.42 Billion ≈ $353.67 Million |
+9.70pp |
| 2010-12-31 | 5.50% | CN¥42.45 Million ≈ $6.21 Million |
CN¥771.69 Million ≈ $112.92 Million |
+0.65pp |
| 2008-12-31 | 4.85% | CN¥31.61 Million ≈ $4.63 Million |
CN¥651.74 Million ≈ $95.37 Million |
+1.13pp |
| 2007-12-31 | 3.72% | CN¥21.90 Million ≈ $3.20 Million |
CN¥588.65 Million ≈ $86.14 Million |
+3.71pp |
| 2006-12-31 | 0.01% | CN¥50.00K ≈ $7.32K |
CN¥579.39 Million ≈ $84.78 Million |
-0.22pp |
| 2003-12-31 | 0.23% | CN¥1.45 Million ≈ $212.24K |
CN¥636.09 Million ≈ $93.08 Million |
-0.12pp |
| 2002-12-31 | 0.35% | CN¥1.99 Million ≈ $290.86K |
CN¥567.42 Million ≈ $83.03 Million |
-3.41pp |
| 2001-12-31 | 3.76% | CN¥29.35 Million ≈ $4.30 Million |
CN¥781.36 Million ≈ $114.34 Million |
-1.47pp |
| 2000-12-31 | 5.23% | CN¥35.45 Million ≈ $5.19 Million |
CN¥678.36 Million ≈ $99.26 Million |
+1.14pp |
| 1999-12-31 | 4.09% | CN¥26.97 Million ≈ $3.95 Million |
CN¥659.36 Million ≈ $96.49 Million |
+2.53pp |
| 1998-12-31 | 1.56% | CN¥10.50 Million ≈ $1.54 Million |
CN¥673.16 Million ≈ $98.50 Million |
+0.67pp |
| 1997-12-31 | 0.89% | CN¥5.37 Million ≈ $785.60K |
CN¥606.51 Million ≈ $88.75 Million |
-1.47pp |
| 1996-12-31 | 2.36% | CN¥10.17 Million ≈ $1.49 Million |
CN¥431.22 Million ≈ $63.10 Million |
-- |
About Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more